Kyntra Bio, Inc. (KYNB)
NASDAQ: KYNB · Real-Time Price · USD
5.28
+0.43 (8.87%)
At close: Oct 19, 2026, 4:00 PM EDT
5.28
0.00 (0.00%)
After-hours: Oct 19, 2026, 4:00 PM EDT
Kyntra Bio Revenue
Kyntra Bio had revenue of $-1.47M in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $4.62M, down -37.14% year-over-year. In the year 2025, Kyntra Bio had annual revenue of $6.44M, down -78.26%. That makes Kyntra Bio the 40,206th largest company in the world by revenue and 5,355th in the United States.
Revenue (ttm)
$4.62M
Revenue Growth
-37.14%
P/S Ratio
4.25
Revenue / Employee
$135,765
Employees
34
Market Cap
21.38M
Revenue by Geography
- Europe 5.64M 87.6%
- Japan 797.00K 12.4%
Fiscal year ended Dec 31, 2025 See the full Kyntra Bio breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.44M | -23.18M | -78.26% |
| Dec 31, 2024 | 29.62M | -17.18M | -36.71% |
| Dec 31, 2023 | 46.80M | -93.93M | -66.74% |
| Dec 31, 2022 | 140.73M | -94.58M | -40.19% |
| Dec 31, 2021 | 235.31M | 58.99M | 33.46% |
| Dec 31, 2020 | 176.32M | -80.26M | -31.28% |
| Dec 31, 2019 | 256.58M | 43.62M | 20.48% |
| Dec 31, 2018 | 212.96M | 81.96M | 62.57% |
| Dec 31, 2017 | 131.00M | -52.19M | -28.49% |
| Dec 31, 2016 | 183.19M | 2.36M | 1.31% |
| Dec 31, 2015 | 180.83M | 43.23M | 31.41% |
| Dec 31, 2014 | 137.60M | 35.43M | 34.68% |
| Dec 31, 2013 | 102.17M | 36.24M | 54.96% |
| Dec 31, 2012 | 65.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Marker Therapeutics | 3.55M |
| Neuphoria Therapeutics | 1.17M |
| Cocrystal Pharma | 330.00K |
| aTyr Pharma | 190.00K |
| Impact BioMedical | 35.00K |
| Fractyl Health | 3.00K |
KYNB News
- 6 days ago - Kyntra Bio initiated with a Buy at Maxim on mCRPC potential - TheFly
- 6 days ago - Kyntra Bio initiated with a Buy at Maxim - TheFly
- 18 days ago - Kyntra Bio appoints Singer to its board of directors - TheFly
- 18 days ago - Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors - GlobeNewsWire
- 4 weeks ago - Kyntra Bio initiated with a Buy at Lake Street on prostate cancer potential - TheFly
- 4 weeks ago - Kyntra Bio initiated with a Buy at Lake Street - TheFly
- 4 weeks ago - Kyntra Bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 6 weeks ago - Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire